RTP Mobile Logo

Friday, December 6, 2019, Orlando, Florida, 7:00 AM – 9:30 AM

Data + Perspectives: Exploring the Role of Novel Agents and Emerging Strategies in the Management of Acute Myeloid Leukemia

A Friday Satellite Symposium Preceding the 61st ASH Annual Meeting

This live activity will blend together two distinct content elements — review of important data sets and discussion of actual cases — to focus on one of the most rapidly evolving areas in all of cancer medicine – the role of novel agents and strategies in the management of acute myeloid leukemia (AML). Each of the activity's four modules will contain a case-based discussion and corresponding faculty presentation and center on a specific topic related to the integration of novel agents into the care of patients with AML. To cultivate a more interactive experience, clinicians in attendance at each event will utilize networked iPads® to complete an onsite survey featuring a number of the same questions and topics to be discussed, the results of which will be presented and discussed throughout the program.

Event Details

Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

7:00 AM – 7:30 AM — Registration and Breakfast Buffet
7:30 AM – 9:30 AM — Educational Meeting

Meeting Room
Orange Ballroom (Lower Level)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
Mark Levis, MD, PhD
Director, Adult Leukemia Program
Co-Division Director, Hematologic Malignancies
Professor of Oncology
The Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Daniel A Pollyea, MD, MS
Associate Professor of Medicine
Clinical Director of Leukemia Services
Robert H Allen, MD Chair in Hematology Research
Division of Hematology
University of Colorado School of Medicine
Aurora, Colorado

Richard M Stone, MD
Director, Translational Research
Leukemia Division
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Andrew H Wei, MBBS, PhDD
Adjunct Associate Professor
Monash University
Clinical Hematologist
Head of Human Molecular Genetics
Alfred Hospital
Melbourne, Australia

Neil Love, MD
Research To Practice
Miami, Florida


Event Time
7:00 AM – 7:30 AM — Registration and Breakfast Buffet
7:30 AM – 9:30 AM — Educational Meeting

MODULE 1: Evolving Paradigms in the Up-Front Treatment of Acute Myeloid Leukemia (AML) in Older Patients or Those Ineligible for Intensive Chemotherapy

  • Biologic rationale for targeting Bcl-2 in patients with AML
  • Published efficacy and safety data supporting the FDA approval of venetoclax in combination with a hypomethylating agent or low-dose cytarabine (LDC) as first-line treatment for AML in patients who are ineligible for intensive chemotherapy
  • Incidence of tumor lysis syndrome and other adverse events associated with the use of venetoclax in AML
  • Proposed role of the hedgehog pathway in AML pathogenesis
  • Design, entry criteria and key efficacy and safety findings from the Phase II BRIGHT 1003 trial of glasdegib with LDC versus LDC alone for patients with newly diagnosed AML ineligible for intensive chemotherapy
  • Recent FDA approval of glasdegib and integration into current care

MODULE 2: Assessment, Incidence and Clinical Significance of FLT3 Mutations in AML

  • Incidence and prognostic and predictive relevance of various FLT3 mutations
  • Patient selection for midostaurin and optimal incorporation into current management algorithms
  • Differential mechanisms of action of midostaurin, gilteritinib and quizartinib; implications for efficacy and tolerability
  • Available Phase III efficacy and safety data with gilteritinib (ADMIRAL trial) and quizartinib (QuANTUM-R study) for relapsed/refractory disease with FLT3 mutations
  • Recent FDA approval of gilteritinib for relapsed/refractory AML and appropriate integration into routine practice

MODULE 3: Long-Term Management of AML with IDH Mutation

  • Published research database supporting the FDA approvals of enasidenib and ivosidenib
  • Tolerability of enasidenib and spectrum of serious and non-life-threatening side effects
  • Recognition and management of common side effects and less frequent adverse events observed with ivosidenib
  • Incidence, presentation and management of differentiation syndrome with enasidenib and ivosidenib
  • Early activity and safety data with enasidenib or ivosidenib in combination with chemotherapy for patients with newly diagnosed AML with IDH mutation
  • Other IDH inhibitors in clinical development, including those blocking multiple IDH pathways

MODULE 4: Other Novel Agents and Strategies Under Evaluation for AML

  • Biologic rationale for targeting CD33 in AML; meta-analysis of randomized trials of gemtuzumab ozogamicin with standard induction chemotherapy demonstrating an overall survival benefit for patients without adverse cytogenetics
  • FDA “reapproval” and current clinical role of gemtuzumab ozogamicin
  • Early clinical trial data with and ongoing Phase III evaluation of CC-486 as maintenance therapy for patients with AML in complete remission
  • Early activity and safety data with novel immunotherapeutic approaches (eg, checkpoint inhibitors, chimeric antigen receptor [CAR] T-cell therapy) for AML
  • Available data with and ongoing evaluation of other promising agents in AML

CE Information

Target Audience
This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia (AML).

Learning Objectives
At the conclusion of this activity, participants should be able to:

  • Recognize the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to develop, adapt or refine current diagnostic testing algorithms for patients with AML
  • Analyze how age, performance status and other biologic and disease-related factors affect the selection and sequencing of therapy for patients with various presentations of AML.
  • Assess available research evidence with approved and emerging FLT3 inhibitors, and use this information to guide clinical care and protocol opportunities for patients with newly diagnosed or progressive AML harboring a FLT3 mutation.
  • Develop an understanding of the mechanism of action, available data and current clinical role of available IDH1/2 inhibitors for patients with relapsed/refractory AML and an IDH1 or IDH2 mutation.
  • Evaluate the recent FDA approvals of novel agents targeting Bcl-2 and the hedgehog signaling pathway for patients with newly diagnosed AML ineligible for intensive therapy, and discern how these therapies can be optimally integrated into nonresearch care algorithms.
  • Design and implement a plan of care to prevent, recognize and manage side effects and toxicities associated with recently approved systemic therapies for AML to support quality of life and continuation of treatment.
  • Identify the mechanisms of action and recall new data with investigational agents demonstrating promising activity in AML, and refer appropriate patients for participation in ongoing trials evaluating these approaches.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from AbbVie Inc, Agios Pharmaceuticals Inc, Astellas Pharma Global Development Inc, Celgene Corporation, Daiichi Sankyo Inc and Genentech.


Hilton Orlando
6001 Destination Parkway
Orlando, FL 32819
Hotel Phone: (407) 313-4300

Meeting Room
Orange Ballroom (Lower Level)

The Hilton Orlando hotel is conveniently located within walking distance of the Orange County Convention Center, where the ASH Annual Meeting is taking place.



This activity is intended for hematologists, medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of acute myeloid leukemia.

There is no registration fee for this event. However, preregistration is advised as seating is limited.

Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

Please note, a limited number of seats are currently available for nonclinicians on a first come, first served basis.

Registration for other/industry professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.